Ascendis Pharma A (ASND) Cash from Investing Activities (2014 - 2026)
Ascendis Pharma A (ASND) posted Cash from Investing Activities of -$7.9 million for Q1 2026, down 100.29% sequentially from -$3.9 million in Q4 2025, and down 969.14% YoY from $909636.5 in Q1 2025.
Ascendis Pharma A (ASND) Cash from Investing Activities (2014 - 2026) Analysis & Trends
Ascendis Pharma A has reported Cash from Investing Activities for 13 years, with the latest figure at -$7.9 million in Q1 2026.
- Quarterly Cash from Investing Activities fell 969.14% year-over-year to -$7.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$16.8 million (down 1532.97% YoY) and the FY2025 annual result came in at -$9.9 million, down 234.11% from the prior year.
- Cash from Investing Activities declined to -$7.9 million in Q1 2026 per ASND's latest filing, from -$3.9 million in the prior quarter.
- Over five years, Cash from Investing Activities peaked at $226.1 million in Q1 2023 and troughed at -$7.9 million in Q1 2026.
- A 5-year average of $21.5 million and a median of $654747.6 in 2024 frame the typical range for Cash from Investing Activities.
- The sharpest annual moves came in 2023 and 2026: Cash from Investing Activities jumped 980.06% in 2023, then sank 969.14% in 2026.
- Over 5 years, Cash from Investing Activities stood at -$813137.2 in 2022, then jumped by 980.06% to $7.2 million in 2023, then sank by 105.5% to -$393243.1 in 2024, then plunged by 903.77% to -$3.9 million in 2025, then slumped by 100.29% to -$7.9 million in 2026.
- According to Business Quant data, Cash from Investing Activities over the past three periods registered -$7.9 million, -$3.9 million, and -$61959.9 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | -45.80 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | -92.70 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -1.66 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | -49.35 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 19.77 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | -229.72 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | -363.46 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 24.51 Mn |
| 10 | Ascendis Pharma A | 15.40 Bn | 14.73 Bn | 268.20 Mn | -7.91 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -7.91 Mn |
| Mar 31, 2026 | -7.91 Mn |
| Dec 31, 2025 | -3.95 Mn |
| Dec 31, 2025 | -3.95 Mn |
| Sep 30, 2025 | -61,959.92 |
| Sep 30, 2025 | -61,959.92 |
| Jun 30, 2025 | -4.91 Mn |
| Jun 30, 2025 | -4.91 Mn |
| Mar 31, 2025 | -739,474.76 |
| Mar 31, 2025 | -739,474.76 |
| Dec 31, 2024 | -393,243.11 |
| Dec 31, 2024 | -393,243.11 |
| Sep 30, 2024 | -552,404.41 |
| Sep 30, 2024 | -552,404.41 |
| Jun 30, 2024 | 654,747.65 |
| Jun 30, 2024 | 654,747.65 |
| Mar 31, 2024 | 7.77 Mn |
| Mar 31, 2024 | 7.77 Mn |
| Dec 31, 2023 | 7.16 Mn |
| Dec 31, 2023 | 7.16 Mn |